【標(biāo)題速讀】【Nm】【2022年】【2-6月】
聲明：本專欄主要對生命科學(xué)領(lǐng)域的一些期刊文章標(biāo)題進(jìn)行翻譯，所有內(nèi)容均由本人手工整理翻譯。由于本人專業(yè)為生物分析相關(guān)，其他領(lǐng)域如果出現(xiàn)翻譯錯誤請諒解。
Fowler et. al report their primary analysis of the ELARA phase 2 trial of tisagenlecleucel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, that showed a robust response and manageable safety profile in heavily pre-treated patients with relapsed/refractory follicular lymphoma. Captured in a moment of suspense, the illustrated cover casts a retro space-age mood over the scene as a tisagenlecleucel CAR T cell recognizes and targets a CD19-expressing follicular lymphoma within the tumor microenvironment, highlighting the selective and specific mechanism of this novel cellular therapy.
Fowler等報告了他們對tisagenlecleucel（CAR T細(xì)胞藥物）的ELARA 2期試驗(yàn)的初步分析，tisagenlecleucel是一種自體抗CD19嵌合抗原受體（CAR）T細(xì)胞療法，該療法在經(jīng)過大量預(yù)處理的復(fù)發(fā)/難治性濾泡性淋巴瘤患者中顯示出強(qiáng)烈的反應(yīng)和可控的安全性。插圖封面捕捉到一個懸念時刻，當(dāng)tisagenlecleucel CAR T細(xì)胞識別并靶向腫瘤微環(huán)境中表達(dá)CD19的濾泡性淋巴瘤時，插圖封面為場景投下了復(fù)古太空時代的氣氛，突出了這種新型細(xì)胞療法的選擇性和特異性治療機(jī)制。
1.AAV gene therapy for Tay-Sachs disease.
AAV基因療法治療Tay-Sachs病。
2.Activity-dependent spinal cord neuromodulation rapidly restores trunk and leg motor functions after complete paralysis.
依賴活動的脊髓神經(jīng)調(diào)控在完全癱瘓后迅速恢復(fù)軀干和腿部運(yùn)動功能。
3.Human pluripotent stem-cell-derived islets ameliorate diabetes in non-human primates.
人類多能干細(xì)胞衍生的胰島能改善非人類靈長類動物的糖尿病。
4.The role of antibody responses against glycans in bioprosthetic heart valve calcification and deterioration.
針對糖類的抗體反應(yīng)在生物假體心臟瓣膜鈣化和惡化中的作用。
5.Metabolomic and microbiome profiling reveals personalized risk factors for coronary artery disease.
代謝組和微生物組分析揭示了冠狀動脈疾病的個性化風(fēng)險因素。
6.Microbiome and metabolome features of the cardiometabolic disease spectrum.
心臟代謝性疾病譜的微生物組和代謝組特征。
7.Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
腸道Akkermansia muciniphila預(yù)測晚期非小細(xì)胞肺癌患者對PD-1阻斷療法的臨床反應(yīng)。
8.Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
Tisagenlecleucel治療成人復(fù)發(fā)或難治性濾泡性淋巴瘤：2期ELARA試驗(yàn)。
9.Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication.
抗GD2與CD47阻斷協(xié)同作用，介導(dǎo)腫瘤的根除。
10.HLA-independent T cell receptors for targeting tumors with low antigen density.
靶向低抗原密度腫瘤的HLA無關(guān)的T細(xì)胞受體。
11.T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
與黑色素瘤患者免疫檢查點(diǎn)阻斷療法的毒性有關(guān)的T細(xì)胞特征。
12.Influenza virus infection history shapes antibody responses to influenza vaccination.
流感病毒感染史影響了對流感疫苗接種的抗體反應(yīng)。
13.A single residue in influenza virus H2 hemagglutinin enhances the breadth of the B cell response elicited by H2 vaccination.
流感病毒H2血凝素中的一個單一殘基增強(qiáng)了H2疫苗接種所引起的B細(xì)胞反應(yīng)的廣度。
14.Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial.
鐵蛋白納米顆粒H2流感疫苗在健康成人中的安全性和免疫原性：一項1期試驗(yàn)。
15.Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial.
IL-15超級拮抗劑N-803對HIV感染者的安全性和病毒學(xué)影響：1期試驗(yàn)。
16.Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.
異源AD5-nCOV加CoronaVac與同源CoronaVac疫苗接種：一項隨機(jī)的4期試驗(yàn)。
17.Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection.
與COVID-19疫苗接種或SARS-CoV-2感染有關(guān)的心肌炎、心包炎和心律失常的風(fēng)險。
亞馬遜的健康
Local communities protect the Amazon rainforest from illegal logging and mining, but this is threatened by a lack of local healthcare. Journalist Sofia Moutinho traveled with a medical team who delivered vaccines for COVID-19 and other supplies during a monthlong boat trip along the Amazon River.
當(dāng)?shù)厣鐓^(qū)保護(hù)亞馬遜雨林免受非法伐木和采礦的侵害，但這受到當(dāng)?shù)蒯t(yī)療保健缺乏的威脅。記者索菲亞·穆蒂尼奧（Sofia Moutinho）與一支醫(yī)療隊一起旅行，該醫(yī)療隊在亞馬遜河沿岸為期一個月的游船之旅中運(yùn)送了COVID-19疫苗和其他物資。
1.An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies.
具有傳染性的SARS-CoV-2 B.1.1.529 Omicron病毒能逃脫治療性單克隆抗體的中和。
2.Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
通過感染或接種疫苗對SARS-CoV-2的尖峰蛋白進(jìn)行三次接觸，可對所有關(guān)注的變體產(chǎn)生卓越的中和免疫力。
3.SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland.
蘇格蘭孕婦的SARS-CoV-2感染和COVID-19疫苗接種率。
4.Whole-genome risk prediction of common diseases in human preimplantation embryos.
人類植入前胚胎中常見疾病的全基因組風(fēng)險預(yù)測。
5.Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain.
造血干細(xì)胞移植化療導(dǎo)致小膠質(zhì)細(xì)胞衰老和外周巨噬細(xì)胞在大腦中吞噬。
6.Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial.
口服小分子螯合劑對自閉癥譜系障礙青少年的安全性和目標(biāo)參與：一個開放標(biāo)簽的1b/2a期試驗(yàn)。
7.Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma.
腸道微生物組與免疫檢查點(diǎn)抑制劑在晚期黑色素瘤中的反應(yīng)的跨隊列關(guān)聯(lián)。
8.Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1.
抗PD-1治療的黑色素瘤患者的臨床反應(yīng)和免疫相關(guān)不良事件的腸道微生物群特征。
9.Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
干細(xì)胞結(jié)構(gòu)驅(qū)動骨髓增生異常綜合征進(jìn)展并預(yù)測對基于venetoclax療法的反應(yīng)。
10.The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.
SGLT2抑制劑empagliflozin在急性心衰住院患者中的應(yīng)用：一項多國隨機(jī)試驗(yàn)。
11.Deep learning-enabled assessment of cardiac allograft rejection from endomyocardial biopsies.
基于深度學(xué)習(xí)的心內(nèi)膜活檢對心臟異體移植排斥的評估。
12.Long-term cardiovascular outcomes of COVID-19.
COVID-19的長期心血管結(jié)果。
癌癥研究的未來
This special Focus issue presents an overview of the most promising developments in cancer research, with an eye toward delivering research and care that is innovative, equitable, sustainable and patient-focused. The cover presents an artistic rendition of the study by Seliger and colleagues, in this issue, showing an increased risk of death by suicide in patients with cancer and underscoring the need for comprehensive psycho-oncological therapy during routine clinical practice to improve the quality of life of such patients.
本期《焦點(diǎn)》特刊概述了癌癥研究中最有前途的發(fā)展，著眼于提供創(chuàng)新、公平、可持續(xù)和以患者為中心的研究和護(hù)理。封面展示了Seliger及其同事在本期中的研究的藝術(shù)再現(xiàn)，顯示癌癥患者自殺死亡的風(fēng)險增加，并強(qiáng)調(diào)在常規(guī)臨床實(shí)踐中需要綜合心理腫瘤治療以提高這類患者的生活質(zhì)量。
1.Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Nivolumab加ipilimumab，補(bǔ)充或不補(bǔ)充活細(xì)菌治療轉(zhuǎn)移性腎細(xì)胞癌：隨機(jī)1期試驗(yàn)。
2.Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.
抗CD19 CAR T細(xì)胞治療后反應(yīng)和毒性的腸道微生物組相關(guān)因素。
3.PSMA-targeting TGFβ-insensitive armored CAR T?cells in metastatic castration-resistant prostate cancer: a phase 1 trial.
PSMA靶向TGFβ不敏感的鎧甲CAR T細(xì)胞治療轉(zhuǎn)移性耐閹割前列腺癌：1期試驗(yàn)。
4.Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial.
Axicabtagene ciloleucel作為高危大B細(xì)胞淋巴瘤的一線治療：2期ZUMA-12試驗(yàn)。
5.Single-cell transcriptomics reveals a distinct developmental state of KMT2A-rearranged infant B-cell acute lymphoblastic leukemia.
單細(xì)胞轉(zhuǎn)錄組學(xué)揭示了KMT2A重排的嬰兒B細(xì)胞急性淋巴細(xì)胞白血病的獨(dú)特發(fā)展?fàn)顟B(tài)。
6.Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism.
基于可操作的S100A9/RAGE抗性機(jī)制，對放射敏感的腦轉(zhuǎn)移瘤進(jìn)行分層。
7.Ulcerative colitis is characterized by a plasmablast-skewed humoral response associated with disease activity.
潰瘍性結(jié)腸炎的特點(diǎn)是與疾病活動相關(guān)的質(zhì)粒偏斜的體液反應(yīng)。
8.In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial.
體內(nèi)局部基因治療隱性萎縮性表皮松解癥：1期和2期試驗(yàn)。
9.Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
腺相關(guān)病毒基因治療血友病A后，轉(zhuǎn)基因mRNA和蛋白質(zhì)生產(chǎn)的個體間差異。
10.Pancreatic islet cryopreservation by vitrification achieves high viability, function, recovery and clinical scalability for transplantation.
通過玻璃化技術(shù)冷凍胰島實(shí)現(xiàn)了高存活率、高功能、高恢復(fù)率和臨床移植的可擴(kuò)展性。
11.The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial.
SGLT2抑制劑canagliflozin治療心力衰竭：CHIEF-HF遠(yuǎn)程、以患者為中心的隨機(jī)試驗(yàn)。
12.Metabolomic profiling reveals extensive adrenal suppression due to inhaled corticosteroid therapy in asthma.
代謝組分析顯示哮喘病人吸入皮質(zhì)類固醇治療導(dǎo)致的廣泛腎上腺抑制。
13.Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial.
mRNA-1273三期COVE試驗(yàn)期間病毒動態(tài)和循環(huán)病毒變體的初步分析。
14.Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England.
英格蘭COVID-19加強(qiáng)型疫苗對COVID-19相關(guān)癥狀、住院和死亡的有效性。
15.Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.
巴西異源性CoronaVac加BNT162b2的疫苗有效性。
16.Increased global integration in the brain after psilocybin therapy for depression.
迷幻藥治療抑郁癥后，大腦中的全局整合增加。
移植中的多基因風(fēng)險評分
Shaked et al. applied a polygenic risk score for type 2 diabetes to liver and kidney transplant donors and recipients with the aim of identifying genetic associations with the development of post-transplantation diabetes mellitus. The cover is illustrative of genetic puzzle pieces in both the donor and the recipient, which can be leveraged to inform and develop personalized treatment strategies and to optimize donor–recipient matching.
Shaked等將2型糖尿病的多基因風(fēng)險評分應(yīng)用于肝腎移植供體和受體，目的是確定與移植后糖尿病發(fā)展的遺傳關(guān)聯(lián)。封面說明了捐贈者和接受者的基因拼圖，可用于告知和制定個性化治療策略并優(yōu)化捐贈者與接受者的匹配。
1.Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial.
基于血液的腫瘤突變負(fù)擔(dān)作為非小細(xì)胞肺癌中阿特唑侖的生物標(biāo)志物：2期B-F1RST試驗(yàn)。
2.Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA.
來自突變的PIK3CA的公共新抗原的免疫原性和治療目標(biāo)。
3.Electronic cigarettes versus nicotine patches for smoking cessation in pregnancy: a randomized controlled trial.
電子煙與尼古丁貼片在妊娠期戒煙中的比較：隨機(jī)對照試驗(yàn)。
4.Dorzagliatin in drug-na?ve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
Dorzagliatin用于2型糖尿病患者的藥物治療：隨機(jī)、雙盲、安慰劑對照的3期試驗(yàn)。
5.Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial.
Dorzagliatin在2型糖尿病患者中作為二甲雙胍的附加治療：一項隨機(jī)、雙盲、安慰劑對照的3期試驗(yàn)。
6.Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes.
2型糖尿病的表型、疾病進(jìn)展和藥物反應(yīng)的異質(zhì)性。
7.The MHC class I MICA gene is a histocompatibility antigen in kidney transplantation.
MHC I類MICA基因是腎臟移植的組織相容性抗原。
8.Donor and recipient polygenic risk scores influence the risk of post-transplant diabetes.
捐贈者和接受者的多基因風(fēng)險評分影響移植后糖尿病的風(fēng)險。
9.Development of a clinical polygenic risk score assay and reporting workflow.
開發(fā)臨床多基因風(fēng)險評分檢測和報告工作流程。
10.Intravitreal antisense oligonucleotide sepofarsen in Leber congenital amaurosis type 10: a phase 1b/2 trial.
玻璃體內(nèi)反義寡核苷酸sepofarsen治療Leber先天性失明10型：1b/2期試驗(yàn)。
11.Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial.
AAV8傳遞廣譜中和抗體在成人HIV感染者中的安全性和耐受性：一個1期的劑量遞增試驗(yàn)。
12.Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.
年輕成年人在SARS-CoV-2人體挑戰(zhàn)中的安全性、耐受性和病毒動力學(xué)。
13.Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
強(qiáng)化mRNA-1273后對SARS-CoV-2的免疫反應(yīng)：一個開放標(biāo)簽的2期試驗(yàn)。
14.Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19.
兒童多系統(tǒng)炎癥綜合征和小兒COVID-19中的免疫病理學(xué)特征。
15.Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants.
mRNA-1273對SARS-CoV-2 Omicron和Delta變體的療效。
16.Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
普通人群在接種兩劑ChAdOx1或BNT162b2疫苗后的抗體反應(yīng)和保護(hù)的相關(guān)因素。
17.Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants.
基于CRISPR的微流控平臺用于呼吸道病毒的臨床測試和SARS-CoV-2變種的鑒定。
中和Omicron子系
In this issue, Bruel et al. demonstrate substantial differences in the sensitivity of the SARS-CoV-2 Delta variant and Omicron sublineages BA.1 and BA.2 to neutralization by nine therapeutic monoclonal antibodies. The cover combines an image of SARS-CoV-2-infected cells fusing with neighboring cells to form syncytia with a view of Earth, reflective of the ongoing global impact of the pandemic.
在這個問題上，Bruel等人表明SARS-CoV-2 Delta變體和Omicron亞系 BA.1 和 BA.2 對九種治療性單克隆抗體中和的敏感性存在顯著差異。封面結(jié)合了一張受SARS-CoV-2感染的細(xì)胞與鄰近細(xì)胞融合形成合胞體的圖像以及地球視角，反映了這一流行病對全球的持續(xù)影響。
1.Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial.
Sotigalimab和/或nivolumab與化療用于一線轉(zhuǎn)移性胰腺癌：隨機(jī)2期PRINCE試驗(yàn)的臨床和免疫學(xué)分析。
2.Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial.
高危III期黑色素瘤新輔助治療ipilimumab和nivolumab后的個性化反應(yīng)導(dǎo)向的手術(shù)和輔助治療：PRADO試驗(yàn)。
3.Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results.
Claudin18.2特異性CAR T細(xì)胞治療胃腸道癌癥：1期試驗(yàn)中期結(jié)果。
4.Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort.
Pembrolizumab治療具有三級淋巴結(jié)構(gòu)的軟組織肉瘤：2期PEMBROSARC試驗(yàn)隊列。
5.In utero origin of myelofibrosis presenting in adult monozygotic twins.
呈現(xiàn)在成年單卵雙胞胎中的骨髓纖維化的子宮內(nèi)起源。
6.A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia.
用于理解異質(zhì)性和預(yù)測急性髓性白血病藥物反應(yīng)的細(xì)胞層次框架。
7.Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial.
數(shù)字化遠(yuǎn)程監(jiān)控加常規(guī)護(hù)理與口服抗癌藥物治療患者的常規(guī)護(hù)理：隨機(jī)的3期CAPRI試驗(yàn)。
8.Swarm learning for decentralized artificial intelligence in cancer histopathology.
癌癥組織病理學(xué)中分散式人工智能的蜂群學(xué)習(xí).
9.Machine learning model to predict mental health crises from electronic health records.
從電子健康記錄中預(yù)測心理健康危機(jī)的機(jī)器學(xué)習(xí)模型。
10.Brain lesions disrupting addiction map to a common human brain circuit.
擾亂成癮的腦部病變映射到一個共同的人類大腦回路。
11.Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial.
利妥昔單抗與托西單抗治療類風(fēng)濕性關(guān)節(jié)炎：4期R4RA隨機(jī)試驗(yàn)中基于滑膜活檢的生物標(biāo)志物分析。
12.Empagliflozin add-on therapy to closed-loop insulin delivery in type 1 diabetes: a 2?×?2 factorial randomized crossover trial.
Empagliflozin對1型糖尿病閉環(huán)胰島素輸送的附加治療：一個2×2因子的隨機(jī)交叉試驗(yàn)。
13.Noninvasive proteomic biomarkers for alcohol-related liver disease.
酒精相關(guān)肝病的非侵入性蛋白質(zhì)組生物標(biāo)志物。
14.Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial.
三合一廣泛中和單克隆抗體治療HIV-1的安全性和抗病毒活性：1期臨床試驗(yàn)。
15.Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
接受單克隆抗體治療的患者血清中和SARS-CoV-2 Omicron亞系BA.1和BA.2的情況。
16.A multisystem, cardio-renal investigation of post-COVID-19 illness.
對COVID-19后疾病的多系統(tǒng)、心腎功能的調(diào)查。
17.COVID-19 and resilience of healthcare systems in ten countries.
在十個國家，COVID-19和醫(yī)療系統(tǒng)的復(fù)原力。
